<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genomics</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med Genomics</journal-id><journal-id journal-id-type="pmc-domain-id">573</journal-id><journal-id journal-id-type="pmc-domain">bmcmedgeno</journal-id><journal-title-group><journal-title>BMC Medical Genomics</journal-title></journal-title-group><issn pub-type="epub">1755-8794</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10259050</article-id><article-id pub-id-type="pmcid-ver">PMC10259050.1</article-id><article-id pub-id-type="pmcaid">10259050</article-id><article-id pub-id-type="pmcaiid">10259050</article-id><article-id pub-id-type="pmid">37308972</article-id><article-id pub-id-type="doi">10.1186/s12920-023-01561-4</article-id><article-id pub-id-type="publisher-id">1561</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Gene S-phase kinase associated protein 2 is a novel prognostic marker in human neoplasms</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Li</surname><given-names initials="GS">Guo-Sheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Huang</surname><given-names initials="T">Tao</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="HF">Hua-Fu</given-names></name><address><email>zhouhuafu_gxmu@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412594.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2961</institution-id><institution>Department of Cardiothoracic Surgery, </institution><institution>The First Affiliated Hospital of Guangxi Medical University, </institution></institution-wrap>Nanning, Guangxi Zhuang Autonomous Region China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.460081.b</institution-id><institution>Department of Cardiothoracic Vascular Surgery, </institution><institution>The Affiliated Hospital of Youjiang Medical University for Nationalities, </institution></institution-wrap>Baise, Guangxi Zhuang Autonomous Region China </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">425450</issue-id><elocation-id>128</elocation-id><history><date date-type="received"><day>12</day><month>6</month><year>2022</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-19 00:25:23.140"><day>19</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12920_2023_Article_1561.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Neoplasms are a series of diseases affecting human health. Prognostic and tumor status&#8211;related markers for various tumors should be identified.</p></sec><sec><title>Methods</title><p id="Par2">Based on 19,515 samples from multiple sources, for the first time, this study provided an overview of gene S-phase kinase associated protein 2 (<italic toggle="yes">SKP2</italic>) in pan-cancer. Differential <italic toggle="yes">SKP2</italic> expression in multiple comparison groups was identified by the Kruskal&#8211;Wallis test and Wilcoxon rank-sum test. The prognosis significance of <italic toggle="yes">SKP2</italic> in individuals with neoplasm was evaluated through univariate Cox regression analysis and Kaplan-Meier curves. The area under the curve was utilized to detect the accuracy of <italic toggle="yes">SKP2</italic> in predicting cancer status. Spearman&#8217;s rank correlation coefficients were calculated in all correlation analyses. Gene set enrichment analysis was used to identify essential signaling pathways of <italic toggle="yes">SKP2</italic> in human neoplasms.</p></sec><sec><title>Results</title><p id="Par3">The study disclosed the upregulated <italic toggle="yes">SKP2</italic> expression in 15 neoplasms and decreased <italic toggle="yes">SKP2</italic> expression in three cancers (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). The transcription factor Forkhead Box M1 may contribute to the increased expression levels of <italic toggle="yes">SKP2</italic> in certain tumors. Over-expressed <italic toggle="yes">SKP2</italic> represented a risk factor for the prognosis of most cancer patients (hazard ratio&#8201;&gt;&#8201;1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). <italic toggle="yes">SKP2</italic> expression made it feasible to distinguish neoplasm and control tissues of 21 neoplasms (sensitivity&#8201;=&#8201;0.79, specificity&#8201;=&#8201;0.87, area under the curve&#8201;=&#8201;0.90), implying its potential in screening a series of neoplasms. Further, the research revealed the close association of <italic toggle="yes">SKP2</italic> expression with DNA methyltransferases, mismatch repair genes, microsatellite instability, tumor mutational burden, neoantigen count, and immunity.</p></sec><sec><title>Conclusions</title><p id="Par4"><italic toggle="yes">SKP2</italic> plays an essential role in multiple neoplasms and may serve as a marker for treating and identifying these neoplasms.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12920-023-01561-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cancer biology</kwd><kwd>Expression</kwd><kwd>Prognosis</kwd><kwd>Immunology</kwd><kwd>Biomarker</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par5">Neoplasms are a series of diseases affecting human health and are the important causes of human death worldwide. It was predicted that in 2020 alone, there would be approximately 20&#160;million newly diagnosed neoplasm patients and about 10&#160;million related deaths worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. Although the clinical therapeutic effect on certain tumors has been significantly improved, the prognosis of most tumor patients is not satisfactory [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. Delay in diagnosis is a fundamental reason for the poor prognosis of tumor patients, and neoplasms are frequently diagnosed at an advanced stage [<xref ref-type="bibr" rid="CR4">4</xref>]. Efforts should therefore be focused on prognostic and tumor status&#8211;related markers for various types of neoplasms.</p><p id="Par6">The gene S-phase kinase associated protein 2 (<italic toggle="yes">SKP2</italic>) is located on chromosome 5p13.2 of human chromosome 5, and its homonymous encoded protein is a member of the F-box protein family [<xref ref-type="bibr" rid="CR5">5</xref>]. <italic toggle="yes">SKP2</italic> has significant carcinogenic characteristics due to its complex functions, such as participation in cell cycle regulation. The carcinogenic characteristics of <italic toggle="yes">SKP2</italic> have been verified in several mouse experiments [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], which highlights the potential of the gene for targeted therapy. In addition, in various cancers, <italic toggle="yes">SKP2</italic> is differentially (mainly highly) expressed in cancer tissues versus control tissues. For example, elevated expression of <italic toggle="yes">SKP2</italic> and its association with poor prognosis were reported in breast and prostate cancer [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Cell experiments have also supported the promotion of <italic toggle="yes">SKP2</italic> in cancer progression [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Thus, current studies consistently reveal the essential roles of <italic toggle="yes">SKP2</italic> in multiple tumors. However, there are no reports focusing on <italic toggle="yes">SKP2</italic> in pan-cancer. Moreover, the potential clinical significance of <italic toggle="yes">SKP2</italic> (e.g., distinguishing tumor patients from individuals without cancer) and the immune correlation of the gene in a variety of tumors are unclear.</p><p id="Par7">The current study comprehensively highlights the expression levels and clinical roles (e.g., prognosis) of <italic toggle="yes">SKP2</italic> in a series of neoplasms based on thousands of samples from several sources. Further, the associations of <italic toggle="yes">SKP2</italic> expression with DNA methyltransferases (DNMTs), mismatch repair genes (MMRGs), microsatellite instability (MSI), tumor mutational burden (TMB), neoantigen count, and immunity (e.g., filtration levels of immune cells) were also revealed, which may promote understanding of <italic toggle="yes">SKP2</italic> in pan-cancers.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Collection and processing of datasets and cohorts</title><p id="Par8">An <italic toggle="yes">SKP2</italic> mRNA expression dataset of normal organs was downloaded from GTEx [<xref ref-type="bibr" rid="CR11">11</xref>], and the dataset included 8,671 human samples. A dataset from CCLE [<xref ref-type="bibr" rid="CR12">12</xref>], including 457 specimens of neoplasm cell lines, was obtained from DepMap Portal. Moreover, a TCGA (The Cancer Genome Atlas) cohort of 33 kinds of neoplasms containing 9,358 neoplasm and 722 control samples was derived from the Xena database. A &#8220;TARGET-AML&#8221; dataset was also acquired from the Xena database, including 173 LAML (acute myeloid leukemia) patients; among the 173 patients, 169 were with chromosome 5 alternations, including t(3;5)(q25;q34), del5q, and monosomy 5. Given the imbalanced sample size (169 versus 4) for the TARGET-AML dataset, the synthetic minority oversampling technique (SMOTE) algorithm of the &#8220;DMwR&#8221; package was used to synthesize a new dataset (16 versus 8) to validate the results based on the TARGET-AML dataset. The expression value of each gene in the mRNA-related datasets listed above was normalized with log<sub>2</sub> (<italic toggle="yes">x</italic>&#8201;+&#8201;1) conversion.</p><p id="Par9">A total of 134 samples (three normal lung samples were used as control groups for both the LUAD and LUSC groups; Supplementary Material&#160;<xref rid="MOESM1" ref-type="media">1</xref>) from THPA [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] were included for validating SKP2 expression at protein levels. The inclusion criteria for these specimens were as follows: (1) immunohistochemical staining for SKP2 protein involved both the neoplasm group and the control group rather than a single neoplasm group or control group; (2) both the neoplasm group and the control group contained at least two specimens; and (3) neoplasm tissues and normal tissues were processed with the same antibody. The criteria for staining scores were: 0, 1, 2, and 3 for negative, weak, moderate, and intense staining levels of SKP2 protein, respectively, while the quantity scores were: 0, 1, 2, and 3 for none, &lt;&#8201;25%, 75&#8211;25%, and &gt;&#8201;75% of stained cells. The total immunohistochemical score represented the SKP2 protein levels for each sample and was evaluated by the staining intensity score and the quantity score.</p></sec><sec id="Sec4"><title>Collection of clinical information</title><p id="Par10">Clinical features, containing age, gender, and AJCC (American Joint Committee on Cancer) stage, were downloaded from the Xena database for the TCGA cohort. The four kinds of prognosis information&#8212;OS (overall survival), DSS (disease-specific survival time), DFI (disease-free interval), and PFI (progression-free interval)&#8212;were also obtained in the Xena database.</p></sec><sec id="Sec5"><title>Extraction of expression data of specific genes</title><p id="Par11">Transcription factors (TFs) that may upregulate <italic toggle="yes">SKP2</italic> expression were predicted from the Cistrome Data Browser [<xref ref-type="bibr" rid="CR15">15</xref>], and ChIP-Seq (chromatin immunoprecipitation followed by sequencing) data of certain TFs were also downloaded from this database. The mRNA expression data of TFs were extracted from the TCGA cohort. The expression levels of three DNMTs (DNMT1, etc.), five MMRGs (MLH1, etc.), and 46 immune checkpoints (BTLA, etc.) were also extracted in the TCGA cohort.</p></sec><sec id="Sec6"><title>Collection of other data</title><p id="Par12">All the MSI, TMB, and immune neoantigen count data for patients in the TCGA cohort were downloaded from SangerBox (3.0) [<xref ref-type="bibr" rid="CR16">16</xref>]. Immune cell infiltration levels and three kinds of scores&#8212;stromal score, immune score, and ESTIMATE score&#8212;for individuals in the TCGA cohort were downloaded from TIMER [<xref ref-type="bibr" rid="CR17">17</xref>] and SangerBox (3.0), respectively, and the data were calculated via the corresponding TIMER and ESTIMATE algorithms.</p><p id="Par13">A gene set called &#8220;c2.cp.kegg.v7.4.symbols&#8221; was downloaded from MSigDB (v7.5.1) for exploring the underlying mechanisms of <italic toggle="yes">SKP2</italic> in multiple neoplasms in terms of KEGG (Kyoto Encyclopedia of Genes and Genomes) [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>] signaling pathways.</p><p id="Par14">CRISPR (clustered regularly interspaced short palindromic repeats) data downloaded from DepMap Portal were used to explore whether <italic toggle="yes">SKP2</italic> was an essential gene for a series of cancer cells. The gene effect was utilized to evaluate the possibility of <italic toggle="yes">SKP2</italic> as an essential cancer gene &#8212; the lower the gene effect score, the higher the likelihood that <italic toggle="yes">SKP2</italic> was essential for cancer cell lines (zero scores suggesting not essential).</p><p id="Par15">The half-maximal inhibitory concentration (IC50) data of 57 drugs approved by the American Food and Drug Administration or verified by clinical trials were obtained from CellMiner [<xref ref-type="bibr" rid="CR22">22</xref>]. The data were applied to explore the susceptibility of certain drugs for patients with distinct <italic toggle="yes">SKP2</italic> expression levels and to identify potential drugs for treating these individuals.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par16">The chi-square test was used to detect the equilibrium of baseline data between comparison groups (e.g., cancer group versus control group). The difference in SKP2 expression in various compared groups was identified via the Kruskal&#8211;Wallis test and Wilcoxon rank-sum test. Multiple comparisons were also performed using the false discovery rate method to assess whether there was a significant difference in <italic toggle="yes">SKP2</italic> mRNA expression between neoplasms and control groups. The Wilcoxon rank-sum test was used to compare the expression levels of TFs between cancer and control groups, and Spearman&#8217;s rank correlation coefficients were utilized to evaluate the relationship between TF expression and <italic toggle="yes">SKP2</italic> expression.</p><p id="Par17">The prognosis effect of <italic toggle="yes">SKP2</italic> for neoplasms patients was assessed by univariate Cox regression analysis and Kaplan-Meier curves. The area under the curve (AUC) was applied to detect the accuracy of <italic toggle="yes">SKP2</italic> in predicting cancer status. Spearman&#8217;s rank correlation coefficients were calculated in all correlation analyses. Gene set enrichment analysis (GSEA) was applied for searching KEGG pathways based on the clusterProfiler package [<xref ref-type="bibr" rid="CR23">23</xref>]. Except for the summary receiver operating characteristic curve, which was generated in Stata (v15.0), all other analyses were carried out in R (v4.1.0). A <italic toggle="yes">p</italic>-value of less than 0.05 suggested statistical significance.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Differential <bold><italic toggle="yes">SKP2</italic></bold> expression in neoplasms</title><p id="Par18">Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> shows the overall design of this study. Balanced age and gender distributions were detected among the cancer and control groups for most cancers (<italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05; Supplementary Materials &#160;<xref rid="MOESM2" ref-type="media">2</xref> and <xref rid="MOESM3" ref-type="media">3</xref>). Various organs of humans were detected with distinct <italic toggle="yes">SKP2</italic> expression levels (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05); for example, the cervix uteri and heart were observed increasing and decreasing <italic toggle="yes">SKP2</italic> expression levels, respectively (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). Similarly, differential <italic toggle="yes">SKP2</italic> expression was detected in different cell lines of neoplasms (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B), and such a phenomenon was also found in tissues of 18 types of 21 investigated neoplasms &#8212; high <italic toggle="yes">SKP2</italic> expression in 15 neoplasms (bladder urothelial carcinoma [BLCA], etc.) and low <italic toggle="yes">SKP2</italic> expression in three neoplasms &#8212; KICH (kidney chromophobe), PRAD (prostate adenocarcinoma), and THCA (thyroid carcinoma) (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C).</p><p id="Par19">Considering the imbalanced age distribution between COAD (colon adenocarcinoma), LIHC (liver hepatocellular carcinoma), and UCEC (uterine corpus endometrial carcinoma) and their control groups (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Supplementary Material&#160;<xref rid="MOESM2" ref-type="media">2</xref>), adjustment tests were carried out. The results showed that, for both the old (&#8805;&#8201;65 years old) and the young (&lt;&#8201;65 years old), <italic toggle="yes">SKP2</italic> expression levels in the COAD, LIHC, and UCEC groups were higher than those in their control groups (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>D), consistent with the results without adjustment tests (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C). The gender distribution between BLCA and its control was also imbalanced (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Supplementary Material&#160;<xref rid="MOESM3" ref-type="media">3</xref>), while the further adjustment test supported an increased <italic toggle="yes">SKP2</italic> expression level in the BLCA group compared to its control group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>E). Therefore, compared with the control tissues, the mRNA expression of <italic toggle="yes">SKP2</italic> in most cancers was significantly different.</p><p id="Par20">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Overview of the study. DNMT, DNA methyltransferase; MMR, mismatch repair; MSI, microsatellite instability; TMB, tumor mutational burden</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e619" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig1_HTML.jpg"/></fig>
</p><p id="Par21">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><italic toggle="yes">SKP2</italic> expression in pan-cancer and its correlations with clinical characteristics. <italic toggle="yes">SKP2</italic> expression in normal tissues (panel A), neoplasms cell lines (panel B), and pan-cancer (panels C&#8211;E). Panels D&#8211;E: Adjustment analysis of <italic toggle="yes">SKP2</italic> expression in certain neoplasms. For panels C&#8211;E: <sup>*</sup><italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, <sup>**</sup><italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, <sup>***</sup><italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; <italic toggle="yes">p</italic>-value is based on the Wilcoxon rank-sum test (multiple comparison test by false discovery rate)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e658" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig2_HTML.jpg"/></fig>
</p><p id="Par22">In addition to mRNA level, we evaluated the expression of SKP2 in various cancers and their control tissues at the protein level. For CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD, HNSCC (head and neck squamous cell carcinoma), kidney cancer, LIHC, LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), STAD (stomach adenocarcinoma), and UCEC, in comparison to normal tissues, the staining intensity of anti-SKP2 antibody was significantly stronger in cancer tissues (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A), while the converse trend was investigated in THCA (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). Moreover, increasing SKP2 protein levels in CESC, COAD, and STAD were confirmed by statistical analysis (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B), consistent with the results at the mRNA level. Although no significant differences in SKP2 protein levels were found between cancer tissues and control tissues for the other nine neoplasms (e.g., BLCA), the expression of SKP2 at both protein and mRNA levels exhibited the same trends for most of these neoplasms (Supplementary Material&#160;<xref rid="MOESM4" ref-type="media">4</xref>).</p><p id="Par23">According to the above results, <italic toggle="yes">SKP2</italic> was upregulated in up to 15 cancers discussed in this research. TFs tend to play essential roles in gene expression regulation. TFs that may regulate <italic toggle="yes">SKP2</italic> expression in the 15 cancers were investigated, which may contribute to understanding possible mechanisms for the overexpression of <italic toggle="yes">SKP2</italic>. A total of 200 TFs that may upregulate <italic toggle="yes">SKP2</italic> expression were obtained from the Cistrome Data Browser. Among these TFs, FOXM1 (forkhead box M1) is encoded by the gene <italic toggle="yes">FOXM1</italic>. <italic toggle="yes">FOXM1</italic> was highly expressed in the 15 cancers (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Supplementary Material&#160;<xref rid="MOESM5" ref-type="media">5</xref>A), where elevated <italic toggle="yes">SKP2</italic> expression was also detected. Moreover, significantly positive correlations were found between the expression levels of <italic toggle="yes">FOXM1</italic> and <italic toggle="yes">SKP2</italic> (<italic toggle="yes">&#961;</italic>&#8201;&#8805;&#8201;0.3, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Supplementary Material&#160;<xref rid="MOESM5" ref-type="media">5</xref>B). What is important is that the binding peaks of FOXM1 can be observed upstream of the transcription start site of <italic toggle="yes">SKP2</italic> (Supplementary Material&#160;<xref rid="MOESM5" ref-type="media">5</xref>C). These results indicated that elevated FOXM1 expression might contribute to the high <italic toggle="yes">SKP2</italic> expression in the 15 cancers.</p><p id="Par24">Notably, the possible mechanisms of SKP2 expression in cancers may be complex. For example, chromosome 5 alternations (<italic toggle="yes">SKP2</italic> is located on chromosome 5) are commonly observed in LAML [<xref ref-type="bibr" rid="CR24">24</xref>]. Compared to the group without chromosome 5 alternations, a trend of downregulation of <italic toggle="yes">SKP2</italic> expression levels can be observed in LAML patients with chromosome 5 alternations, based on the raw data (Supplementary Material&#160;<xref rid="MOESM6" ref-type="media">6</xref>A). The result was validated via the SMOTE data (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, Supplementary Material&#160;<xref rid="MOESM6" ref-type="media">6</xref>B). This suggests that, except for the regulatory effect of TFs, attention should also be given to other factors that may affect SKP2 expression in specific cancers. Thus, the underlying mechanisms of SKP2 expression in cancers require further investigation.</p><p id="Par25">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Validation of SKP2 expression in neoplasms at protein levels. Panel A: Elevated SKP2 protein levels were detected in most neoplasm (except BLCA, PRAD, and THCA) tissues rather than corresponding normal tissues; images are available from v21.0.proteinatlas.org. The three numbers at the lower left of each panel indicate patient identify document, staining level, and quantity, respectively. Panel B: Elevated SKP2 protein levels can be detected in CESC, COAD, and STAD; <sup>*</sup><italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; <italic toggle="yes">p</italic>-value is based on the Wilcoxon rank-sum test</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e771" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec10"><title>Clinical characteristics of patients with various <bold><italic toggle="yes">SKP2</italic></bold> expression levels</title><p id="Par26">Patients with different clinical characteristics may have various prognoses. For example, cancer patients with advanced AJCC stages tend to have poorer prognoses than others. Thus, we analyzed the relationship between <italic toggle="yes">SKP2</italic> expression and available clinical characteristics data of patients. The results showed that increased <italic toggle="yes">SKP2</italic> expression tended to be observed in advanced AJCC stages for certain neoplasms (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A and Supplementary Material&#160;<xref rid="MOESM7" ref-type="media">7</xref>). Elevated <italic toggle="yes">SKP2</italic> expression was observed in male instead of female patients with HNSCC, LAML, or READ (rectum adenocarcinoma); in contrast, the opposite phenomenon was found in KIRP (kidney renal papillary cell carcinoma) and SARC (sarcoma) (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Supplementary Material&#160;<xref rid="MOESM8" ref-type="media">8</xref>). Individuals with cancer of different ages exhibited varying levels of <italic toggle="yes">SKP2</italic> expression. For instance,&#160;decreasing&#160;<italic toggle="yes">SKP2</italic> expression was also detected in older patients with BRCA (breast invasive carcinoma) and young patients with PCPG (pheochromocytoma and paraganglioma) (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Supplementary Material&#160;<xref rid="MOESM9" ref-type="media">9</xref>).</p><p id="Par27">Given that <italic toggle="yes">SKP2</italic> expression was associated with at least two clinical characteristics among five neoplasms (BRCA, KIRP, LIHC, LUAD, and READ), covariate analysis was performed for these neoplasms. Consequently, AJCC stage distribution was correlated with age distribution in KIRP (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Supplementary Material&#160;<xref rid="MOESM10" ref-type="media">10</xref>) and, thus, further adjustment analysis was carried out for this cancer. For patients with this cancer at AJCC stage I, males were observed to have lower <italic toggle="yes">SKP2</italic> expression than females (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B); this discrepancy was not identified for KIRP at stages II, III, or IV (Supplementary Material&#160;<xref rid="MOESM11" ref-type="media">11</xref>). For KIRP, a positive association between <italic toggle="yes">SKP2</italic> expression and AJCC stage was determined not for females but for males (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C and Supplementary Material&#160;<xref rid="MOESM11" ref-type="media">11</xref>).</p><p id="Par28">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Correlations between <italic toggle="yes">SKP2</italic> expression with clinical parameters. For panels A&#8211;C, the <italic toggle="yes">p</italic>-value is based on the Wilcoxon rank-sum test</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e868" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec11"><title>Prognosis differences of patients with disparate <bold><italic toggle="yes">SKP2</italic></bold> expression levels</title><p id="Par29">To directly evaluate the prognostic significance of <italic toggle="yes">SKP2</italic> expression in various tumors, univariate Cox regression analyses and Kaplan-Meier curves were performed in this research. The two analysis methods consistently indicated that elevated <italic toggle="yes">SKP2</italic> expression represented poor OS and/or DSS for patients with ACC (adrenocortical carcinoma), KICH, KIRP, LGG (brain lower grade glioma), LIHC, MESO (mesothelioma), PRAD, SKCM (skin cutaneous melanoma), or THCA (hazard ratio [HR]&#8201;&gt;&#8201;1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) and favorable OS and DSS for individuals with OV (ovarian serous cystadenocarcinoma), READ, or THYM (thymoma) (HR&#8201;&lt;&#8201;1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A&#8211;D). In DFI and PFI, <italic toggle="yes">SKP2</italic> expression also played a risk role for patients with ACC and KIRP (HR&#8201;&gt;&#8201;1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>A&#8211;D). Moreover, <italic toggle="yes">SKP2</italic> expression was significantly correlated with poor PFI in individuals with KICH, LGG, LIHC, MESO, or UVM (uveal melanoma) (HR&#8201;&gt;&#8201;1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), as well as with considerable PFI in OV patients (HR&#8201;&lt;&#8201;1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>B and D).</p></sec><sec id="Sec12"><title>Difference in cancer status of patients with distinct <bold><italic toggle="yes">SKP2</italic></bold> expression levels</title><p id="Par30">The prognostic significance of <italic toggle="yes">SKP2</italic> expression in various cancers was notable, but it was still unclear whether <italic toggle="yes">SKP2</italic> could distinguish cancer samples from control samples, which was analyzed in this study. In 21 kinds of neoplasms investigated in this part, <italic toggle="yes">SKP2</italic> well differentiated 15 types of neoplasm (BLCA, etc.) tissues and their normal counterparts (AUC&#8201;&gt;&#8201;0.75) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>A). Particularly, <italic toggle="yes">SKP2</italic> expression had a remarkable capacity to differentiate eight cancers from their control tissues; the eight neoplasms were BLCA, CESC, COAD, ESCA (esophageal carcinoma), GBM (glioblastoma multiforme), LUSC, PCPG (pheochromocytoma and paraganglioma), and READ (AUC&#8201;&gt;&#8201;0.90) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>A). <italic toggle="yes">SKP2</italic> expression made it feasible to discern the neoplasm and control tissues of the 21 cancers (sensitivity&#8201;=&#8201;0.79, specificity&#8201;=&#8201;0.87, AUC&#8201;=&#8201;0.90) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>B), particularly for the 15 cancers listed above (sensitivity&#8201;=&#8201;0.83, specificity&#8201;=&#8201;0.91, AUC&#8201;=&#8201;0.94) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>C).</p><p id="Par31">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Relation of <italic toggle="yes">SKP2</italic> expression with overall survival (panels A&#8211;B) and disease-specific survival of neoplasm patients (panels C&#8211;D)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e965" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig5_HTML.jpg"/></fig>
</p><p id="Par32">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Relation of <italic toggle="yes">SKP2</italic> expression with disease-free interval (panels A&#8211;B) and progression-free interval of neoplasm patients (panels C&#8211;D)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e980" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig6_HTML.jpg"/></fig>
</p><p id="Par33">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Receiver operating characteristic curves for detecting the ability of <italic toggle="yes">SKP2</italic> expression to distinguish neoplasm tissues from their normal tissues. Panel A: Receiver operating characteristic curves. Panels B&#8211;C: Summary receiver operating characteristic curves. AUC, area under the curve</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e995" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig7_HTML.jpg"/></fig>
</p><p id="Par34">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Spearman coefficient of <italic toggle="yes">SKP2</italic> expression with DNA methyltransferase expression (panel A), mismatch repair gene expression (panel B), microsatellite instability (panel C), tumor mutational burden (panel D), and immune neoantigen count (panel E). The letter &#8220;&#961;&#8221; is followed by the Spearman correlation coefficient</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1010" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig8_HTML.jpg"/></fig>
</p></sec><sec id="Sec1345"><title><bold><italic toggle="yes">SKP2</italic></bold> expression with DNMTs, MMRGs, MSI, and TMB</title><p id="Par37">DNMTs, MMRGs, MSI, and TMB are considered prognostic markers and treatment indicators of cancer [<xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. Exploring the relationship between <italic toggle="yes">SKP2</italic> and these indicators may help identify the marker role of <italic toggle="yes">SKP2</italic> in neoplasms. A significantly positive correlation between <italic toggle="yes">SKP2</italic> expression and the expression levels of three DNMTs and five MMRGs was detected in almost all the 33 cancers analyzed (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>A and B). The close association of <italic toggle="yes">SKP2</italic> expression with MSI and TMB was also observed in multiple neoplasms, especially for DLBC (lymphoid neoplasm diffuse large B-cell lymphoma) (<italic toggle="yes">&#961;</italic> = &#8722;0.51, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) in MSI&#160;(Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>C), as well as KICH, LUAD (lung adenocarcinoma), and READ in TMB&#160;(<italic toggle="yes">&#961;</italic>&#8201;&gt;&#8201;0.3, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>D). These results suggest that <italic toggle="yes">SKP2</italic> may affect the progression of neoplasms by influencing DNMTs, MMRGs, MSI, and TMB.</p></sec><sec id="Sec13"><title><bold><italic toggle="yes">SKP2</italic></bold> expression with immunity</title><p id="Par38">Elevated MSI and TMB tend to increase immune neoantigen levels [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]; thus, the relationship between immune neoantigen count and <italic toggle="yes">SKP2</italic> expression was investigated. As a result, the positive relevance of immune neoantigen count with <italic toggle="yes">SKP2</italic> expression was detected in SARC, TGCT (testicular germ cell tumors), and LUAD (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>E). The immune neoantigen can potentially induce an immune response, which involves activating a variety of immune cells. Interestingly, significant correlations (generally positive) between the <italic toggle="yes">SKP2</italic> expression and infiltration levels of most of the six immune cells &#8212; B cells, CD4 T cells, CD8 T cells, neutrophil cells, macrophage cells, and dendritic cells &#8212; were observed in THYM, KICH, and KIRC (kidney renal clear cell carcinoma) (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>A). Furthermore, <italic toggle="yes">SKP2</italic> was also closely related to the immune microenvironment, including immune cells. For instance, for ACC, SKCM, TGCT, and GBM, negative associations between <italic toggle="yes">SKP2</italic> expression and immune environment (including stromal, immune, and ESTIMATE scores) were detected (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>B). Notably, the relationship between <italic toggle="yes">SKP2</italic> expression and both immune cell infiltration levels and immune environment scores varied with tumor type (Supplementary Materials&#160;<xref rid="MOESM12" ref-type="media">12</xref> and <xref rid="MOESM13" ref-type="media">13</xref>), implying the complex mechanisms of <italic toggle="yes">SKP2</italic> in neoplasms.</p><p id="Par39">Immune checkpoints are known to regulate the growth and proliferation of immune cells negatively. In our study, <italic toggle="yes">SKP2</italic> expression was relevant to the expression levels of multiple immune checkpoints. Particularly, the close correlation (<italic toggle="yes">&#961;</italic>&#8201;&gt;&#8201;0.3, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) between <italic toggle="yes">SKP2</italic> expression and at least 15 immune checkpoints can be detected in DLBC, KIRC, PRAD, and UVM&#160;(Supplementary Material&#160;<xref rid="MOESM14" ref-type="media">14</xref>), which may partly explain the correlations between <italic toggle="yes">SKP2</italic> expression and the immune environment.</p></sec><sec id="Sec14"><title><bold><italic toggle="yes">SKP2</italic></bold> expression with GSEA</title><p id="Par40"><italic toggle="yes">SKP2</italic> plays an essential role in multiple neoplasms, and the corresponding mechanisms require investigation. Previous studies have revealed the molecular mechanism of the gene in a single neoplasm, but whether <italic toggle="yes">SKP2</italic> had a similar molecular mechanism in a variety of tumors was unknown. Therefore, we attempted to clarify this issue via GSEA. Among the 26 KEGG signaling pathways with a GSEA <italic toggle="yes">p</italic>-value less than 0.05, the &#8220;olfactory transduction&#8221; pathway was observed in 11 neoplasms (Supplementary Materials&#160;<xref rid="MOESM15" ref-type="media">15</xref> and <xref rid="MOESM16" ref-type="media">16</xref>), highlighting the critical role of this pathway in multiple neoplasms. Additionally, <italic toggle="yes">SKP2</italic> was found to be associated with specific signaling pathways (e.g., &#8220;complement and coagulation cascades,&#8221; &#8220;cytokine&#8211;cytokine receptor interaction,&#8221; and &#8220;metabolism of xenobiotics by cytochrome P450&#8221;) in at least two cancers (Supplementary Material&#160;<xref rid="MOESM16" ref-type="media">16</xref>), which required further experimental investigation. At the same time, it is also necessary to further study the molecular mechanism of <italic toggle="yes">SKP2</italic> in specific cancers. For example, <italic toggle="yes">SKP2</italic> may play its roles in GBM and SARC through complex mechanisms (at least five signaling pathways) (Supplementary Materials&#160;<xref rid="MOESM17" ref-type="media">17</xref> and <xref rid="MOESM18" ref-type="media">18</xref>).</p></sec><sec id="Sec141"><title>Importance of <bold><italic toggle="yes">SKP2</italic></bold> in a variety of cancer cells and exploration of potential targeted drugs</title><p id="Par43">We further verified the vital role of <italic toggle="yes">SKP2</italic> in various tumors through CRISPR data. The CRISPR results demonstrated the essential cancer role of <italic toggle="yes">SKP2</italic> in a series of neoplasms, including BLCA, CESC, COAD, ESCA, STAD, LIHC, SKCM, PRAD, SARC, THCA, UCS&#160;(uterine carcinosarcoma), and UVM (gene effect&#8201;&lt;&#8201;0) (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>C). In other words, in these neoplasm cells, those with low <italic toggle="yes">SKP2</italic> expression tend to be depleted, suggesting <italic toggle="yes">SKP2</italic> can promote the development of these neoplasms.</p><p id="Par44">The above results indicate the importance of <italic toggle="yes">SKP2</italic> in multiple neoplasms, and the gene may be a potential marker for the treatment of several cancers. Thus, a drug sensitivity analysis for <italic toggle="yes">SKP2</italic> was carried out. Through the analysis results based on CellMiner data, 19 types of 57 drugs approved by the American Food and Drug Administration or verified by clinical trials may benefit cancer patients with high-<italic toggle="yes">SKP2</italic> expression, as cancer cells with upregulated <italic toggle="yes">SKP2</italic> expression were susceptible to these drugs based on the results of IC50 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig10" ref-type="fig">10</xref>).</p><p id="Par45">
<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p><italic toggle="yes">SKP2</italic> expression with the immune microenvironment, and its essential role in some cancer types. Panels A&#8211;B: The relevance between <italic toggle="yes">SKP2</italic> expression with infiltration levels of immune cells (panel A) and immune-related scores (panel B). Panel C: <italic toggle="yes">SPK2</italic> was identified as an essential cancer gene with a gene effect score of less than 0 in most cancers</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1240" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig9_HTML.jpg"/></fig>
</p><p id="Par46">
<fig id="Fig10" position="float" orientation="portrait"><label>Fig. 10</label><caption><p>Drug sensitivity of <italic toggle="yes">SKP2</italic>. Drugs with a <italic toggle="yes">p</italic>-value of less than 0.01 are shown in this figure. <sup>**</sup><italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; <sup>***</sup><italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; <italic toggle="yes">p</italic>-value is based on the Wilcoxon rank-sum test. IC50, half-maximal inhibitory concentration</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1272" position="float" orientation="portrait" xlink:href="12920_2023_1561_Fig10_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p id="Par47">Based on 19,515 samples from several sources, for the first time in an overview of pan-cancer, this study disclosed the overexpression of <italic toggle="yes">SKP2</italic> and its risk factor for the prognosis of patients in multiple neoplasms. The increased expression levels of <italic toggle="yes">SKP2</italic> in tumors may result from regulation of the TF FOXM1. <italic toggle="yes">SKP2</italic> expression made it feasible to distinguish the neoplasm and control tissues of 21 neoplasms, implying its potential in screening a series of neoplasms. Further, the study also investigated the associations between <italic toggle="yes">SKP2</italic> expression and several factors including DNMTs, MMRGs, MSI, TMB, neoantigen count, and immunity, as well as conducted GSEA, and examined drug susceptibility. The study identified the potential of <italic toggle="yes">SKP2</italic> as a marker for the treatment and identification of these neoplasms. It also provided clues to understanding the underlying mechanisms of pan-cancer.</p><p id="Par48"><italic toggle="yes">SKP2</italic> is upregulated in most tumors. Previously, the elevated expression level of <italic toggle="yes">SKP2</italic> was identified in a few cancers, such as COAD [<xref ref-type="bibr" rid="CR30">30</xref>] and oral squamous cell carcinoma [<xref ref-type="bibr" rid="CR31">31</xref>]. In our study, distinct <italic toggle="yes">SKP2</italic> expression was found in various normal organ and neoplasm cells. Moreover, <italic toggle="yes">SKP2</italic> mRNA was found to be highly expressed in 15 tumors &#8212; BLCA, CESC, CHOL, COAD, ESCA, GBM, HNSCC, KIRC, LIHC, LUAD, LUSC, PCPG, READ, STAD, and UCEC, and the overexpression status of SKP2 in cancer tissues of CESC, COAD, and STAD was verified at the protein level. By contrast, a low expression of <italic toggle="yes">SKP2</italic> mRNA was observed in tissues of KICH, PRAD, and THCA. Taken together, the overexpression of <italic toggle="yes">SKP2</italic> was identified in most neoplasms.</p><p id="Par49">The regulation mechanisms of SKP2 expression in tumors remain unclear. Based on our study, the increased expression levels of <italic toggle="yes">SKP2</italic> in tumors may result from regulation of the TF FOXM1, as evidenced by (1) the high expression of both <italic toggle="yes">FOXM1</italic> and <italic toggle="yes">SKP2</italic> in 15 cancers (CESC, etc.); (2)&#160;positive correlations between the expressions of <italic toggle="yes">FOXM1</italic> and <italic toggle="yes">SKP2&#160;</italic>in the 15 tumors; and (3)&#160;the presence of binding peaks of FOXM1 upstream of the transcription start site of <italic toggle="yes">SKP2</italic>. However, the possible mechanisms of <italic toggle="yes">SKP2</italic> expression in cancers may be complicated. An example is that a downregulation of <italic toggle="yes">SKP2</italic> expression levels was identified in LAML patients with chromosome 5 alternations compared to those without chromosome 5 alternations. In addition to this, according to previous studies, amplification of the <italic toggle="yes">SKP2</italic> locus was reported in certain cancers, such as in lung cancer, biliary tract cancer, and glioblastoma [<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref>], which may contribute to the upregulation of <italic toggle="yes">SKP2</italic> in these cancers at transcriptional levels. However, considering that the number of samples with gene amplification was far smaller than that of samples with high <italic toggle="yes">SKP2</italic> expression in certain cancers (e.g., small-cell lung carcinoma) [<xref ref-type="bibr" rid="CR35">35</xref>], it is possible that high SKP2 expression cannot be attributed solely to gene amplification. Indeed, abnormal SKP2 expression was also identified in the absence of <italic toggle="yes">SKP2</italic> locus amplification, and regulation at post-transcriptional levels may play a role in this process [<xref ref-type="bibr" rid="CR36">36</xref>]. Thus, further research is needed to explore the mechanisms of high SKP2 expression in tumors.</p><p id="Par50">High expression of <italic toggle="yes">SKP2</italic> is related to the poor prognosis of tumors. Bochis et al. [<xref ref-type="bibr" rid="CR30">30</xref>] revealed that high <italic toggle="yes">SKP2</italic> expression predicted higher tumor-node-metastasis stages in patients with COAD and was related to poor OS and relapse-free survival. Yamada et al. [<xref ref-type="bibr" rid="CR31">31</xref>] identified that over-expressed <italic toggle="yes">SKP2</italic> was a signal of poor prognosis for patients with oral squamous cell carcinoma. They confirmed that downregulation of <italic toggle="yes">SKP2</italic> could significantly reduce the migration and invasion ability of oral squamous cell carcinoma cells. In several tumors, such as breast cancer, osteosarcoma, and glioblastoma, overexpression of <italic toggle="yes">SKP2</italic> was associated with poor prognosis [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Based on our pan-cancer study, increased <italic toggle="yes">SKP2</italic> was a risk factor for the prognosis (OS, DSS, DFI, and/or PFI) of individuals with one of ten types of cancers &#8212; ACC, KICH, KIRP, LGG, LIHC,&#160;MESO, PRAD, SKCM, THCA, and UVM &#8212; while it predicted a favorable prognosis in READ, THYM,&#160;and OV patients. Thus, the risk role of upregulated <italic toggle="yes">SKP2</italic> expression is detected in most tumors, demonstrating the clinical value of the gene for prognosis. Based on this finding, a potential practical application example is to detect the expression level of <italic toggle="yes">SKP2</italic> in cancer patients by some techniques (e.g., microarray, RNA-sequence or quantitative polymerase chain reaction) in the future, and to predict the prognosis of the patients according to the expression level of <italic toggle="yes">SKP2</italic>, thereby providing some reference for the clinical management of these patients.</p><p id="Par51">A few studies have reported the potential of <italic toggle="yes">SKP2</italic> as a prognostic marker, but its identification effect on cancer status has not been investigated. Based on the AUC analysis of the current study, <italic toggle="yes">SKP2</italic> is a remarkable molecule to distinguish cancer tissues and normal tissues for various cancers (particularly BLCA,&#160;CESC, COAD, ESCA, GBM,&#160;LUSC, PCPG,&#160;and READ). Such a result suggests that <italic toggle="yes">SKP2</italic> is a potential biomarker for predicting cancer status in multiple tumors.</p><p id="Par52">This study preliminarily discussed the underlying mechanisms of <italic toggle="yes">SKP2</italic> in multiple neoplasms by investigating the correlation of <italic toggle="yes">SKP2</italic> with DNMTs, MMRGs, MSI, and TMB. Epigenetic alterations can influence biological processes (e.g., growth and proliferation) of neoplasms. DNMT-mediated DNA methylation and MMRG-led MMR are common epigenetic modifications, enabling DNMTs and MMRGs to impact disease development. For example, <italic toggle="yes">DNMT1</italic>, <italic toggle="yes">DNMT3A</italic>, and <italic toggle="yes">DNMT3B</italic> have been shown to promote LAML, which may be due to DNMTs silencing certain tumor suppressor genes through hypermethylation of these genes, thereby promoting the progression of LAML [<xref ref-type="bibr" rid="CR25">25</xref>]. Dysfunction of MMRGs may lead to the loss of control of various biological processes, thereby affecting tumor formation and treatment [<xref ref-type="bibr" rid="CR26">26</xref>]. In our study, the expression level of <italic toggle="yes">SKP2</italic> was significantly positively correlated with the expression levels of three DNMTs and five MMRGs, suggesting that the effect of <italic toggle="yes">SKP2</italic> on DNMT and MMR may be one of the critical pathways for the gene to promote cancer. Dysfunctions of MMR can cause MSI, and elevated levels of MSI exhibit high TMB [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Increased MSI and TMB are associated with elevated neoantigen, thereby stimulating or promoting the body&#8217;s immune response; thus, MSI and TMB are considered practical markers for predicting response to immunotherapy [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>]. <italic toggle="yes">SKP2</italic> was not only positively correlated with the MSI and TMB of some cancers (e.g., COAD, READ, and SARC), but also positively associated with immune neoantigen count. This suggests that <italic toggle="yes">SKP2</italic> may also have the potential to predict the immune response to immunotherapy, which requires further investigation.</p><p id="Par53">The relationship between <italic toggle="yes">SKP2</italic> and the immune microenvironment, including immune cell levels, is very complex in many tumors. On the one hand, <italic toggle="yes">SKP2</italic> was positively correlated with six immune cell infiltration levels (B cells, CD4 T cells, CD8 T cells, neutrophil cells, macrophage cells, and dendritic cells) in some tumors (especially THYM, KICH, and KIRC), suggesting that <italic toggle="yes">SKP2</italic> may act as an immune antigen to activate the immune response, thereby causing an increase in immune cell levels. Such a finding has also been supported in some single cancers. For example, Kim et al. [<xref ref-type="bibr" rid="CR44">44</xref>] found that upregulated <italic toggle="yes">SKP2</italic> was positively correlated with the level of regulatory T cell infiltration. Alvaro et al. [<xref ref-type="bibr" rid="CR45">45</xref>] reported that Hodgkin lymphoma cells with high <italic toggle="yes">SKP2</italic> expression had higher T cell infiltration levels than those with low <italic toggle="yes">SKP2</italic> expression. On the other hand, <italic toggle="yes">SKP2</italic> was negatively correlated with immune microenvironment scores in some tumors (such as ACC, SKCM, TGCT,&#160;and GBM), suggesting that <italic toggle="yes">SKP2</italic> may also be involved in significantly negative regulation of the immune microenvironment in these tumors and then affect the prognosis of patients. However, previous research has not provided similar reference information. Therefore, the current studies suggest that <italic toggle="yes">SKP2</italic> may have two sides in immune regulation for different tumors, but further investigations are necessary.</p><p id="Par54">This study also suggested the potential direction of <italic toggle="yes">SKP2</italic> in tumor-related research and the drugs targeting this molecule. The protein encoded by cyclin dependent kinase inhibitor 1B (<italic toggle="yes">CDKN1B</italic>/p27) is a negative regulator of the cell cycle. The complex composed of this protein enables cells to stay in the G1 phase of their cycle and, thus, it has the effect of inhibiting tumors. As a ubiquitin ligase subunit, SKP2 can target to degrade CDKN1B, promote the transformation of cells from the G1 phase to the S phase, and then cause the growth and proliferation of cancer cells; this is considered the typical function of SKP2 [<xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR48">48</xref>]. It is noteworthy that, based on the GSEA focusing on a common potential molecular mechanism in different neoplasms, the olfactory transduction pathway may also be essential for SKP2 to affect cancer progression, as the pathway was observed in up to 11 neoplasms. Indeed, olfactory transduction has been found to be related to the occurrence and development of tumors. For example, a series of olfactory receptors are identified as cancer-driven factors [<xref ref-type="bibr" rid="CR49">49</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref>]. However, whether SKP2 affects the process of cancer through an olfactory transmission mechanism requires further experimental verification. In other aspects, the CRISPR data from DepMap Portal confirmed the essential cancer role of <italic toggle="yes">SKP2</italic> in certain tumors (BLCA, etc.), suggesting that <italic toggle="yes">SKP2</italic> promotes cancer in these tumors. Further, the current study revealed a series of drugs that may be suitable for neoplasm patients with high <italic toggle="yes">SKP2</italic> expression.</p><p id="Par55">This study has certain limitations. Due to limited specimens, <italic toggle="yes">SKP2</italic> mRNA expression differences in various cancers were not verified at the protein level, and there was an imbalance in sample size between the experimental and control groups in the TARGET-AML dataset. In addition, no body-fluid samples were collected to detect <italic toggle="yes">SKP2</italic> screening for pan-cancer. More studies are needed to verify the molecular mechanism of SKP2 in various cancers.</p><p id="Par56">Collectively, this study provided a comprehensive analysis of <italic toggle="yes">SKP2</italic> in human neoplasms. <italic toggle="yes">SKP2</italic> plays an essential role in multiple neoplasms and may serve as a marker for treating and identifying these neoplasms.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec16"><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 1.</bold> THPA samples included in this study for exploring SKP2 protein levels</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 2.</bold> Age distribution differences between cancer group and normal group</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 3.</bold> Gender distribution differences between cancer group and normal group</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM4_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 4.</bold> The SKP2 expression trends at protein levels in multiple neoplasms</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM5_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 5.</bold> The potential association between transcription factor FOXM1 and SKP2 in pan-cancer. Panel A: Expression of FOXM1 was significantly upregulated in 15 human cancer types, as determined by Wilcoxon rank-sum test (multiple comparison test by false discovery rate, **p&#8201;&lt;&#8201;0.01, ***p&#8201;&lt;&#8201;0.001). Panel B: The mRNA expression levels of FOXM1 were positively correlated with those of SKP2 in 15 cancer types (Spearman correlation coefficients are indicated as numerical values). Panel C: ChIP-Seq binding peaks of FOXM1 were observed upstream of SKP2 transcriptional start sites</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM6_ESM.tif" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 6.</bold> SKP2 expression between LAML patients with chromosome 5 alternations and those without chromosome 5 alternations. A: Wilcoxon rank-sum test based on original data. B: Wilcoxon rank-sum test based on SMOTE data</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM7" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM7_ESM.tif" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 7.</bold> The relationship of SKP2 expression with cancer patients&#8217; AJCC stage</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM8" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM8_ESM.tif" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 8.</bold> The relationship of SKP2 expression with cancer patients&#8217; gender</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM9" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM9_ESM.tif" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 9.</bold> The relationship of SKP2 expression with cancer patients&#8217; age</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM10" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM10_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 10.</bold> Identification of covariate between age, gender, and AJCC stage</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM11" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM11_ESM.tif" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 11.</bold> The relationship of SKP2 expression with KIRP patients&#8217; age and AJCC stage</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM12" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM12_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 12.</bold> The associations between SKP2 expression and immune cell infiltration levels</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM13" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM13_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 13.</bold> The associations between SKP2 expression and immune environment</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM14" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM14_ESM.tiff" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 14.</bold> The relationship of SKP2 expression with immune checkpoints gene expression</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM15" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM15_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 15.</bold> KEGG results based on gene set enrichment analysis in this study</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM16" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM16_ESM.pdf" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 16.</bold> A summary of KEGG results based on gene set enrichment analysis in this study</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM17" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM17_ESM.tif" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 17.</bold> The potential signaling pathways of SKP2 in GBM</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM18" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12920_2023_1561_MOESM18_ESM.tif" position="float" orientation="portrait"><caption><p><bold>Supplementary Material 18.</bold> The potential signaling pathways of SKP2 in SARC</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Guo-Sheng Li and Tao Huang contributed equally as co-first authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the anonymous reviewers for their professional comments and suggestions, which significantly improved our manuscript. The results shown in the study are in part based upon data generated by the GTEx, CCLE, THPA, and TCGA.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Guo-Sheng Li, Tao Huang, and Hua-Fu Zhou were responsible for the conception and design of the study, drafting and revising the manuscript, and approving its final version. Guo-Sheng Li and Tao Huang provided the study materials and/or participants, collected and collated the data, and conducted the data analysis and interpretation. Guo-Sheng Li made a contribution to the final analysis validation.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The data supporting pan-cancer analyses&#8217; findings are available in GTEx Portal at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gtexportal.org/home/">https://gtexportal.org/home/</ext-link>, Depmap Portal at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://depmap.org/portal/download/">https://depmap.org/portal/download/</ext-link>, THPA at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.proteinatlas.org/">https://www.proteinatlas.org/</ext-link>, and the Cancer Genome Atlas at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga">https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga</ext-link>.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par58">All methods were carried out in accordance with relevant guidelines and regulations (declarations of Helsinki).</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par59">Not applicable.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par57">Guo-Sheng Li, Tao Huang, and Hua-Fu Zhou declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Wagle</surname><given-names>NS</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2023</article-title><source>CA Cancer J Clin</source><year>2023</year><volume>73</volume><issue>1</issue><fpage>17</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.3322/caac.21763</pub-id><pub-id pub-id-type="pmid">36633525</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>L</given-names></name><name name-style="western"><surname>Devasia</surname><given-names>T</given-names></name><name name-style="western"><surname>Mariotto</surname><given-names>AB</given-names></name><name name-style="western"><surname>Yabroff</surname><given-names>KR</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cancer treatment and survivorship statistics, 2022</article-title><source>CA Cancer J Clin</source><year>2022</year><volume>72</volume><issue>5</issue><fpage>409</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.3322/caac.21731</pub-id><pub-id pub-id-type="pmid">35736631</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudin</surname><given-names>CM</given-names></name><name name-style="western"><surname>Brambilla</surname><given-names>E</given-names></name><name name-style="western"><surname>Faivre-Finn</surname><given-names>C</given-names></name><name name-style="western"><surname>Sage</surname><given-names>J</given-names></name></person-group><article-title>Small-cell lung cancer</article-title><source>Nat Rev Dis Primers</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-00235-0</pub-id><pub-id pub-id-type="pmid">33446664</pub-id><pub-id pub-id-type="pmcid">PMC8177722</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Moten</surname><given-names>A</given-names></name><name name-style="western"><surname>Peng</surname><given-names>D</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Pan</surname><given-names>BS</given-names></name><name name-style="western"><surname>Manne</surname><given-names>R</given-names></name><etal/></person-group><article-title>The Skp2 pathway: a critical target for Cancer Therapy</article-title><source>Semin Cancer Biol</source><year>2020</year><volume>67</volume><issue>Pt 2</issue><fpage>16</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.01.013</pub-id><pub-id pub-id-type="pmid">32014608</pub-id><pub-id pub-id-type="pmcid">PMC9201937</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zvi</surname><given-names>YS</given-names></name><name name-style="western"><surname>Batko</surname><given-names>B</given-names></name><name name-style="western"><surname>Zaphiros</surname><given-names>N</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>EF</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>14294</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-32428-9</pub-id><pub-id pub-id-type="pmid">30250282</pub-id><pub-id pub-id-type="pmcid">PMC6155331</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation</article-title><source>Cell Cycle</source><year>2016</year><volume>15</volume><issue>10</issue><fpage>1344</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1080/15384101.2016.1160986</pub-id><pub-id pub-id-type="pmid">27111245</pub-id><pub-id pub-id-type="pmcid">PMC4889242</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>PL</given-names></name><name name-style="western"><surname>Lin</surname><given-names>DI</given-names></name><name name-style="western"><surname>Lei</surname><given-names>J</given-names></name><name name-style="western"><surname>Fiorentino</surname><given-names>M</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>E</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>MH</given-names></name><etal/></person-group><article-title>The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy</article-title><source>Urol Oncol</source><year>2011</year><volume>29</volume><issue>3</issue><fpage>302</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2009.03.022</pub-id><pub-id pub-id-type="pmid">19450994</pub-id><pub-id pub-id-type="pmcid">PMC5437980</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanamori</surname><given-names>A</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>D</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gotoh</surname><given-names>N</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1</article-title><source>Oncogene</source><year>2020</year><volume>39</volume><issue>39</issue><fpage>6218</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01423-8</pub-id><pub-id pub-id-type="pmid">32826949</pub-id><pub-id pub-id-type="pmcid">PMC7515798</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Cui</surname><given-names>D</given-names></name><etal/></person-group><article-title>SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination</article-title><source>J Exp Clin Cancer Res</source><year>2019</year><volume>38</volume><issue>1</issue><fpage>76</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1069-3</pub-id><pub-id pub-id-type="pmid">30760284</pub-id><pub-id pub-id-type="pmcid">PMC6375223</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Genotype-Tissue</collab></person-group><article-title>Expression (GTEx) project</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><issue>6</issue><fpage>580</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/ng.2653</pub-id><pub-id pub-id-type="pmid">23715323</pub-id><pub-id pub-id-type="pmcid">PMC4010069</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Ghandi M, Huang FW, Jan&#233;-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569(7757):503&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1186-3</pub-id><pub-id pub-id-type="pmcid">PMC6697103</pub-id><pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhlen</surname><given-names>M</given-names></name><name name-style="western"><surname>Fagerberg</surname><given-names>L</given-names></name><name name-style="western"><surname>Hallstrom</surname><given-names>BM</given-names></name><name name-style="western"><surname>Lindskog</surname><given-names>C</given-names></name><name name-style="western"><surname>Oksvold</surname><given-names>P</given-names></name><name name-style="western"><surname>Mardinoglu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Proteomics. Tissue-based map of the human proteome</article-title><source>Science</source><year>2015</year><volume>347</volume><issue>6220</issue><fpage>1260419</fpage><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><pub-id pub-id-type="pmid">25613900</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>AN</given-names></name><name name-style="western"><surname>Dussaq</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kennell</surname><given-names>T</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Willey</surname><given-names>CD</given-names></name><name name-style="western"><surname>Hjelmeland</surname><given-names>AB</given-names></name></person-group><article-title>HPAanalyze: an R package that facilitates the retrieval and analysis of the human protein Atlas data</article-title><source>BMC Bioinformatics</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>463</fpage><pub-id pub-id-type="doi">10.1186/s12859-019-3059-z</pub-id><pub-id pub-id-type="pmid">31500569</pub-id><pub-id pub-id-type="pmcid">PMC6734269</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>R</given-names></name><name name-style="western"><surname>Wan</surname><given-names>C</given-names></name><name name-style="western"><surname>Mei</surname><given-names>S</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>D1</issue><fpage>D729</fpage><lpage>D35</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1094</pub-id><pub-id pub-id-type="pmid">30462313</pub-id><pub-id pub-id-type="pmcid">PMC6324081</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform</article-title><source>iMeta</source><year>2022</year><volume>1</volume><issue>3</issue><fpage>e36</fpage><pub-id pub-id-type="doi">10.1002/imt2.36</pub-id><pub-id pub-id-type="pmcid">PMC10989974</pub-id><pub-id pub-id-type="pmid">38868713</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Traugh</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JS</given-names></name><etal/></person-group><article-title>TIMER: a web server for Comprehensive Analysis of Tumor-Infiltrating Immune cells</article-title><source>Cancer Res</source><year>2017</year><volume>77</volume><issue>21</issue><fpage>e108</fpage><lpage>e10</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0307</pub-id><pub-id pub-id-type="pmid">29092952</pub-id><pub-id pub-id-type="pmcid">PMC6042652</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Furumichi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>M</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morishima</surname><given-names>K</given-names></name></person-group><article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><issue>D1</issue><fpage>D353</fpage><lpage>D61</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id><pub-id pub-id-type="pmid">27899662</pub-id><pub-id pub-id-type="pmcid">PMC5210567</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Furumichi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishiguro-Watanabe</surname><given-names>M</given-names></name></person-group><article-title>KEGG for taxonomy-based analysis of pathways and genomes</article-title><source>Nucleic Acids Res</source><year>2023</year><volume>51</volume><issue>D1</issue><fpage>D587</fpage><lpage>D92</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac963</pub-id><pub-id pub-id-type="pmid">36300620</pub-id><pub-id pub-id-type="pmcid">PMC9825424</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name></person-group><article-title>Toward understanding the origin and evolution of cellular organisms</article-title><source>Protein Sci</source><year>2019</year><volume>28</volume><issue>11</issue><fpage>1947</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1002/pro.3715</pub-id><pub-id pub-id-type="pmid">31441146</pub-id><pub-id pub-id-type="pmcid">PMC6798127</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></name><name name-style="western"><surname>Goto</surname><given-names>S</given-names></name></person-group><article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Res</source><year>2000</year><volume>28</volume><issue>1</issue><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmid">10592173</pub-id><pub-id pub-id-type="pmcid">PMC102409</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinhold</surname><given-names>WC</given-names></name><name name-style="western"><surname>Sunshine</surname><given-names>M</given-names></name><name name-style="western"><surname>Varma</surname><given-names>S</given-names></name><name name-style="western"><surname>Doroshow</surname><given-names>JH</given-names></name><name name-style="western"><surname>Pommier</surname><given-names>Y</given-names></name></person-group><article-title>Using CellMiner 1.6 for Systems Pharmacology and genomic analysis of the NCI-60</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><issue>17</issue><fpage>3841</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0335</pub-id><pub-id pub-id-type="pmid">26048278</pub-id><pub-id pub-id-type="pmcid">PMC4558215</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LG</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>QY</given-names></name></person-group><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><year>2012</year><volume>16</volume><issue>5</issue><fpage>284</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id><pub-id pub-id-type="pmcid">PMC3339379</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herry</surname><given-names>A</given-names></name><name name-style="western"><surname>Douet-Guilbert</surname><given-names>N</given-names></name><name name-style="western"><surname>Morel</surname><given-names>F</given-names></name><name name-style="western"><surname>Le Bris</surname><given-names>MJ</given-names></name><name name-style="western"><surname>De Braekeleer</surname><given-names>M</given-names></name></person-group><article-title>Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML</article-title><source>Eur J Haematol</source><year>2007</year><volume>78</volume><issue>6</issue><fpage>457</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2007.00847.x</pub-id><pub-id pub-id-type="pmid">17391336</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>KK</given-names></name><name name-style="western"><surname>Lawrie</surname><given-names>CH</given-names></name><name name-style="western"><surname>Green</surname><given-names>TM</given-names></name></person-group><article-title>Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute myeloid leukaemia</article-title><source>Biomark Insights</source><year>2019</year><volume>14</volume><fpage>1177271919846454</fpage><pub-id pub-id-type="doi">10.1177/1177271919846454</pub-id><pub-id pub-id-type="pmid">31105426</pub-id><pub-id pub-id-type="pmcid">PMC6509988</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaina</surname><given-names>B</given-names></name></person-group><article-title>Epigenetic regulation of DNA repair genes and implications for tumor therapy</article-title><source>Mutat Res Rev Mutat Res</source><year>2019</year><volume>780</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.mrrev.2017.10.001</pub-id><pub-id pub-id-type="pmid">31395346</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Crown</surname><given-names>J</given-names></name></person-group><article-title>Biomarkers for Predicting Response to Immunotherapy with Immune checkpoint inhibitors in Cancer Patients</article-title><source>Clin Chem</source><year>2019</year><volume>65</volume><issue>10</issue><fpage>1228</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2019.303644</pub-id><pub-id pub-id-type="pmid">31315901</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jardim</surname><given-names>DL</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A</given-names></name><name name-style="western"><surname>de Melo Gagliato</surname><given-names>D</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R</given-names></name></person-group><article-title>The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><issue>2</issue><fpage>154</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.10.001</pub-id><pub-id pub-id-type="pmid">33125859</pub-id><pub-id pub-id-type="pmcid">PMC7878292</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schumacher</surname><given-names>TN</given-names></name><name name-style="western"><surname>Scheper</surname><given-names>W</given-names></name><name name-style="western"><surname>Kvistborg</surname><given-names>P</given-names></name></person-group><article-title>Cancer Neoantigens</article-title><source>Annu Rev Immunol</source><year>2019</year><volume>37</volume><fpage>173</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053402</pub-id><pub-id pub-id-type="pmid">30550719</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasile Bochis</surname><given-names>O</given-names></name><name name-style="western"><surname>Achimas-Cadariu</surname><given-names>P</given-names></name><name name-style="western"><surname>Vlad</surname><given-names>C</given-names></name><name name-style="western"><surname>Fetica</surname><given-names>B</given-names></name><name name-style="western"><surname>Corneliu Leucuta</surname><given-names>D</given-names></name><name name-style="western"><surname>Ioan Busuioc</surname><given-names>C</given-names></name><etal/></person-group><article-title>The prognostic role of Skp2 and the tumor suppressor protein p27 in colorectal cancer</article-title><source>J BUON</source><year>2017</year><volume>22</volume><issue>5</issue><fpage>1122</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">29135092</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>S</given-names></name><name name-style="western"><surname>Yanamoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Naruse</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsushita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Umeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Skp2 regulates the expression of MMP-2 and MMP-9, and enhances the Invasion potential of oral squamous cell carcinoma</article-title><source>Pathol Oncol Res</source><year>2016</year><volume>22</volume><issue>3</issue><fpage>625</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s12253-016-0049-6</pub-id><pub-id pub-id-type="pmid">26874697</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saigusa</surname><given-names>K</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>N</given-names></name><name name-style="western"><surname>Tsuda</surname><given-names>H</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>S</given-names></name><name name-style="western"><surname>Maruno</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoshimine</surname><given-names>T</given-names></name><etal/></person-group><article-title>Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas</article-title><source>Cancer Sci</source><year>2005</year><volume>96</volume><issue>10</issue><fpage>676</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2005.00099.x</pub-id><pub-id pub-id-type="pmid">16232199</pub-id><pub-id pub-id-type="pmcid">PMC11159392</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanada</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>S</given-names></name><name name-style="western"><surname>Arii</surname><given-names>S</given-names></name><name name-style="western"><surname>Yasui</surname><given-names>K</given-names></name><name name-style="western"><surname>Imoto</surname><given-names>I</given-names></name><name name-style="western"><surname>Inazawa</surname><given-names>J</given-names></name></person-group><article-title>Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers</article-title><source>Cancer Sci</source><year>2004</year><volume>95</volume><issue>12</issue><fpage>969</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb03185.x</pub-id><pub-id pub-id-type="pmid">15596046</pub-id><pub-id pub-id-type="pmcid">PMC11158159</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokoi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yasui</surname><given-names>K</given-names></name><name name-style="western"><surname>Mori</surname><given-names>M</given-names></name><name name-style="western"><surname>Iizasa</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujisawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Inazawa</surname><given-names>J</given-names></name></person-group><article-title>Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes</article-title><source>Am J Pathol</source><year>2004</year><volume>165</volume><issue>1</issue><fpage>175</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63286-5</pub-id><pub-id pub-id-type="pmid">15215173</pub-id><pub-id pub-id-type="pmcid">PMC1618537</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokoi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yasui</surname><given-names>K</given-names></name><name name-style="western"><surname>Saito-Ohara</surname><given-names>F</given-names></name><name name-style="western"><surname>Koshikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Iizasa</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujisawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers</article-title><source>Am J Pathol</source><year>2002</year><volume>161</volume><issue>1</issue><fpage>207</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64172-7</pub-id><pub-id pub-id-type="pmid">12107105</pub-id><pub-id pub-id-type="pmcid">PMC1850681</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hammaren</surname><given-names>HM</given-names></name><name name-style="western"><surname>Savitski</surname><given-names>MM</given-names></name><name name-style="western"><surname>Baek</surname><given-names>SH</given-names></name></person-group><article-title>Control of protein stability by post-translational modifications</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>201</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-35795-8</pub-id><pub-id pub-id-type="pmid">36639369</pub-id><pub-id pub-id-type="pmcid">PMC9839724</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Cai</surname><given-names>HQ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q</given-names></name><etal/></person-group><article-title>High S phase kinase-associated protein 2 expression is a potential prognostic biomarker for glioma</article-title><source>Oncol Lett</source><year>2020</year><volume>20</volume><issue>3</issue><fpage>2788</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.3892/ol.2020.11818</pub-id><pub-id pub-id-type="pmid">32782596</pub-id><pub-id pub-id-type="pmcid">PMC7400960</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Nan</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Han</surname><given-names>L</given-names></name><etal/></person-group><article-title>High Skp2/Low p57(Kip2) expression is Associated with poor prognosis in human breast carcinoma</article-title><source>Breast Cancer (Auckl)</source><year>2015</year><volume>9</volume><issue>Suppl 1</issue><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">26309408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4137/BCBCR.S30101</pub-id><pub-id pub-id-type="pmcid">PMC4525793</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chalmers</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Connelly</surname><given-names>CF</given-names></name><name name-style="western"><surname>Fabrizio</surname><given-names>D</given-names></name><name name-style="western"><surname>Gay</surname><given-names>L</given-names></name><name name-style="western"><surname>Ali</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ennis</surname><given-names>R</given-names></name><etal/></person-group><article-title>Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden</article-title><source>Genome Med</source><year>2017</year><volume>9</volume><issue>1</issue><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s13073-017-0424-2</pub-id><pub-id pub-id-type="pmid">28420421</pub-id><pub-id pub-id-type="pmcid">PMC5395719</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hechtman</surname><given-names>JF</given-names></name><name name-style="western"><surname>Middha</surname><given-names>S</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>ZK</given-names></name><name name-style="western"><surname>Zehir</surname><given-names>A</given-names></name><name name-style="western"><surname>Berger</surname><given-names>MF</given-names></name><name name-style="western"><surname>Vakiani</surname><given-names>E</given-names></name><etal/></person-group><article-title>Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations</article-title><source>Fam Cancer</source><year>2017</year><volume>16</volume><issue>4</issue><fpage>525</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s10689-017-9993-x</pub-id><pub-id pub-id-type="pmid">28405781</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mlecnik</surname><given-names>B</given-names></name><name name-style="western"><surname>Bindea</surname><given-names>G</given-names></name><name name-style="western"><surname>Angell</surname><given-names>HK</given-names></name><name name-style="western"><surname>Maby</surname><given-names>P</given-names></name><name name-style="western"><surname>Angelova</surname><given-names>M</given-names></name><name name-style="western"><surname>Tougeron</surname><given-names>D</given-names></name><etal/></person-group><article-title>Integrative analyses of Colorectal Cancer Show Immunoscore is a stronger predictor of patient survival than microsatellite instability</article-title><source>Immunity</source><year>2016</year><volume>44</volume><issue>3</issue><fpage>698</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.025</pub-id><pub-id pub-id-type="pmid">26982367</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name></person-group><article-title>Microsatellite instability: a review of what the oncologist should know</article-title><source>Cancer Cell Int</source><year>2020</year><volume>20</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/s12935-019-1091-8</pub-id><pub-id pub-id-type="pmid">31956294</pub-id><pub-id pub-id-type="pmcid">PMC6958913</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17(4):209&#8211;22.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc.2016.154</pub-id><pub-id pub-id-type="pmcid">PMC5575801</pub-id><pub-id pub-id-type="pmid">28233802</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HK</given-names></name><name name-style="western"><surname>Won</surname><given-names>KY</given-names></name><name name-style="western"><surname>Han</surname><given-names>SA</given-names></name></person-group><article-title>The antioncogenic effect of Beclin-1 and FOXP3 is associated with SKP2 expression in gastric adenocarcinoma</article-title><source>Med (Baltim)</source><year>2021</year><volume>100</volume><issue>33</issue><fpage>e26951</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000026951</pub-id><pub-id pub-id-type="pmcid">PMC8376310</pub-id><pub-id pub-id-type="pmid">34414959</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvaro</surname><given-names>T</given-names></name><name name-style="western"><surname>Lejeune</surname><given-names>M</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>JF</given-names></name><name name-style="western"><surname>Salvado</surname><given-names>MT</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>C</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><issue>3</issue><fpage>685</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1246</pub-id><pub-id pub-id-type="pmid">18245527</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q</given-names></name></person-group><article-title>ZNF292 suppresses proliferation of ESCC cells through ZNF292/SKP2/P27 signaling axis</article-title><source>Chin J Cancer Res</source><year>2021</year><volume>33</volume><issue>6</issue><fpage>637</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.21147/j.issn.1000-9604.2021.06.01</pub-id><pub-id pub-id-type="pmid">35125808</pub-id><pub-id pub-id-type="pmcid">PMC8742179</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lohmuller</surname><given-names>M</given-names></name><name name-style="western"><surname>Roeck</surname><given-names>BF</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>TG</given-names></name><name name-style="western"><surname>Schapfl</surname><given-names>MA</given-names></name><name name-style="western"><surname>Pegka</surname><given-names>F</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>S</given-names></name><etal/></person-group><article-title>The SKP2-p27 axis defines susceptibility to cell death upon CHK1 inhibition</article-title><source>Mol Oncol</source><year>2022</year><volume>16</volume><issue>15</issue><fpage>2771</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.13264</pub-id><pub-id pub-id-type="pmid">35673965</pub-id><pub-id pub-id-type="pmcid">PMC9348596</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>B</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>EL</given-names></name></person-group><article-title>Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition</article-title><source>Br J Cancer</source><year>2022</year><volume>127</volume><issue>6</issue><fpage>969</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-01898-0</pub-id><pub-id pub-id-type="pmid">35752713</pub-id><pub-id pub-id-type="pmcid">PMC9470583</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Shibel R, Sarfstein R, Nagaraj K, Lapkina-Gendler L, Laron Z, Dixit M et al. The olfactory receptor gene product, OR5H2, modulates Endometrial Cancer cells Proliferation via Interaction with the IGF1 Signaling Pathway. Cells. 2021;10(6).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10061483</pub-id><pub-id pub-id-type="pmcid">PMC8231575</pub-id><pub-id pub-id-type="pmid">34204736</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>AL</given-names></name><name name-style="western"><surname>Anadon</surname><given-names>CM</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S</given-names></name><name name-style="western"><surname>Mine</surname><given-names>JA</given-names></name><name name-style="western"><surname>Handley</surname><given-names>KF</given-names></name><name name-style="western"><surname>Payne</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Olfactory receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors</article-title><source>Mol Cancer Ther</source><year>2022</year><volume>21</volume><issue>7</issue><fpage>1184</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-21-0872</pub-id><pub-id pub-id-type="pmid">35499393</pub-id><pub-id pub-id-type="pmcid">PMC9256805</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>C</given-names></name><name name-style="western"><surname>Cho</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name><name name-style="western"><surname>Koo</surname><given-names>J</given-names></name></person-group><article-title>Odorant receptors in cancer</article-title><source>BMB Rep</source><year>2022</year><volume>55</volume><issue>2</issue><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2022.55.2.010</pub-id><pub-id pub-id-type="pmid">35168702</pub-id><pub-id pub-id-type="pmcid">PMC8891625</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>